Australia's most trusted
source of pharma news
Saturday, 10 May 2025
Posted 8 May 2025 AM
Amgen has started legal proceedings to protect its highest earner on the PBS against the biosimilars of Sandoz.
In the first quarter this year Amgen's denosumab portfolio, Prolia and Xgeva, earned $90.8 million in pre-rebate R/PBS reimbursements, a third higher than the same period last year and the seventh highest earner for the quarter. For the 12 months ending 31 March this year, the two drugs earned $324.4 million in reimbursements.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.